Akari Therapeutics Plc Stock Price, News & Analysis

Akari Therapeutics (NASDAQ:AKTX) is advancing research on its novel antibody drug conjugate (ADC) payload PH1, a spliceosome modulator designed for cancer treatment. The company highlighted that PH1 demonstrates multiple mechanisms of action, including cancer cell death induction and immune system activation against tumors.

Key features of PH1 include its ability to target cancers driven by oncogenic factors like KRAS, BRAF, and FGFR3, reduced off-target toxicity through engineered linker technology, and resistance to standard efflux transporters. The company expects to release new preclinical data on PH1's impact against a key oncogenic driver before the end of 2025.

Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs), announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.

During the event, President and CEO Abizer Gaslightwala shared insights about his career journey, his commitment to the company, and his enthusiasm for Akari's development programs. The presentation is now accessible on-demand through virtualinvestorco.com and the company's investor relations website.

Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor segment discussing their recently granted India Patent No. 562,919. The patent, titled "Thailanstatin Analogs," covers the company's PH1 payload, proprietary cleavable and non-cleavable linkers, and ADC technology for cancer treatment applications.

The segment features CEO Abizer Gaslightwala explaining the significance of this patent protection for their immuno-oncology antibody drug conjugates (ADCs) technology platform.

Akari Therapeutics (NASDAQ: AKTX) has secured Patent No. 562,919 in India for its PH1 payload technology, a novel antibody drug conjugate (ADC) for cancer treatment. The patent covers claims for the PH1 payload, proprietary linkers, and ADC technology. PH1 functions as a spliceosome inhibitor designed to disrupt RNA splicing, leading to cancer cell death and immune system activation. This patent strengthens Akari's global IP portfolio, which includes US patents (10,815,246 B2, 10,301,319 B2, 11,691,982 B2) and recent grants in China and Israel. The company is developing a pipeline of ADC candidates showing promising preclinical results in tumor-killing activity and immune system activation. The India patent is particularly significant as cancer cases in the region are projected to reach 2.08 million by 2040.

Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has released a "Meet the Team" video featuring Mark F. Kubik, their newly appointed Head of Business Development – Oncology. The video, which showcases Kubik, an industry leader known for his oncology expertise and successful transaction record leading to multiple approved therapeutic products, is now available on the company's website under the Investors section.

Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on developing novel payload antibody drug conjugates (ADCs), has announced its participation in the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. President and CEO Abizer Gaslightwala will present and discuss recent corporate developments on Thursday, May 29, 2025, at 2:20 PM ET. The presentation will be accessible through a webcast, with registration available for interested participants.

Akari Therapeutics (NASDAQ: AKTX) reported Q1 2025 financial results and provided updates on its ADC development program. The company is developing novel Antibody Drug Conjugates with immuno-oncology payloads for cancer treatment, with its lead asset AKTX-101 targeting Trop2. The company appointed Mark Kubik as Head of Business Development - Oncology.

Financial highlights include a reduced net loss of $3.7 million compared to $5.6 million in Q1 2024. R&D expenses decreased to $0.8 million from $2.3 million, while G&A expenses dropped to $2.7 million from $3.7 million. The company held $2.6 million in cash as of March 31, 2025, with an additional $4.0 million received in April from a March 2025 offering that raised $6.0 million net.

Key upcoming milestones include presenting preclinical data for their PH1 payload ADC in H2 2025, exploring AKTX-101 in various solid tumors, and seeking strategic partnerships.

Akari Therapeutics (NASDAQ: AKTX) has appointed Mark F. Kubik as Head of Business Development - Oncology. Kubik brings over 25 years of experience in transformative deal creation and productive alliances, particularly in ADCs and antibody therapies. His notable achievements include leading transactions at companies like SeaGen (now Pfizer), Abgenix (now Amgen), and OncoImmune, where he orchestrated a $425M sale to Merck. Most recently, he served as Senior VP of U.S and EU Business Development at I-MAB Biopharma. At Akari, Kubik will focus on business development for the company's novel ADC platform and lead asset AKTX-101, a potential first-in-class immuno-oncology ADC therapy targeting Trop2 for multiple solid tumors.

Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing next-generation precision bi-functional antibody drug conjugates (ADC) for cancer treatment, has released a corporate update video featuring their newly appointed President and Chief Executive Officer, Abizer Gaslightwala. The video, released on April 22, 2025, is available on the company's website under the Investors section's Presentations page at www.akaritx.com.